The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; Newlink Genetics; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); ChemoCentryx (Inst); CTI (Inst); Lilly (Inst); Newlink Genetics (Inst); Pfizer (Inst); Plexxikon (Inst); Precision BioLogic (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Axis Pharma; CMM; Peerview
 
Albert C. Lockhart
Research Funding - Bayer (Inst); CTI (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Macrogenics (Inst); Millennium (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teva (Inst); Vertex (Inst); Zenyaku Kogyo (Inst)
 
Benjamin R. Tan
Consulting or Advisory Role - Roche/Genentech
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex
 
Rama Suresh
No Relationships to Disclose
 
Preet Paul Singh
Consulting or Advisory Role - Bayer; Merrimack
 
Kian-Huat Lim
No Relationships to Disclose
 
Katrina Pedersen
No Relationships to Disclose
 
Manik A. Amin
No Relationships to Disclose
 
William G. Hawkins
No Relationships to Disclose
 
David G DeNardo
Research Funding - Verastem (Inst)